source
- BMS beats Q2 forecasts and lifts 2026 outlook despite delays in Cobenfy and milvexian dataBMS reported second‑quarter revenue of $12.97 billion, topping analysts' estimate of $11.73 billion, and earnings per share of $2.04, well above the $1.60 consensus. The strong results prompted the…
- Sanofi books over €1 billion impairment after ending eczema drug and halting two immunology programsSanofi disclosed that it will record more than €1.03 billion in impairment charges for the second quarter. The bulk of the charge stems from the decision to terminate development of an eczema trea…